Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, announces that it will hold a presentation for investors on Tuesday, 30 April 2019.
Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, announces that it will hold a presentation for investors on Tuesday, 30 April 2019.
The briefing by Dr Paul Kerr, CEO of Fusion, will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, London EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email fusion@walbrookpr.com.
Enquiries:
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com |
|
Paul McManus |
Mob: +44 (0)7980 541 893 |
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
